B&D White Capital Company LLC Makes New Investment in Abbott Laboratories $ABT

B&D White Capital Company LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 23,500 shares of the healthcare product maker’s stock, valued at approximately $2,413,000.

Other hedge funds have also recently modified their holdings of the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Stifel Nicolaus decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. JPMorgan Chase & Co. lifted their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, BTIG Research boosted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.61.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $100.69 on Thursday. The firm has a market cap of $175.38 billion, a P/E ratio of 32.59, a P/E/G ratio of 1.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm’s 50 day moving average price is $90.92 and its 200-day moving average price is $101.48.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.51 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.